| Name: | GLYPHIC BIOTECHNOLOGIES, INC. |
| Jurisdiction: | New York |
| Legal type: | FOREIGN BUSINESS CORPORATION |
| Status: | Active |
| Date of registration: | 12 Jul 2022 (3 years ago) |
| Entity Number: | 6534739 |
| ZIP code: | 10005 |
| County: | New York |
| Place of Formation: | Delaware |
| Foreign Legal Name: | GLYPHIC BIOTECHNOLOGIES, INC. |
| Address: | 28 LIBERTY STREET, NEW YORK, NY, United States, 10005 |
| Plan Name | Plan Year | EIN/PN | Received | Sponsor | Total number of participants | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GLYPHIC BIOTECHNOLOGIES 401(K) PLAN | 2023 | 862740771 | 2024-05-08 | GLYPHIC BIOTECHNOLOGIES, INC. | 20 | |||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
| Administrator’s EIN | 474474775 |
| Plan administrator’s name | GUIDELINE, INC. |
| Plan administrator’s address | 1412 CHAPIN AVENUE, BURLINGAME, CA, 94010 |
| Administrator’s telephone number | 8882283491 |
Signature of
| Role | Plan administrator |
| Date | 2024-05-08 |
| Name of individual signing | QIAN LIU |
| File | View Page |
| Three-digit plan number (PN) | 001 |
| Effective date of plan | 2022-01-01 |
| Business code | 541700 |
| Sponsor’s telephone number | 9284597442 |
| Plan sponsor’s address | 169 MADISON AVENUE, #2216, NEW YORK, NY, 10016 |
Plan administrator’s name and address
| Administrator’s EIN | 474474775 |
| Plan administrator’s name | GUIDELINE, INC. |
| Plan administrator’s address | 1412 CHAPIN AVENUE, BURLINGAME, CA, 94010 |
| Administrator’s telephone number | 8882283491 |
Signature of
| Role | Plan administrator |
| Date | 2023-06-02 |
| Name of individual signing | CHRISTINE RIMER |
| Name | Role | Address |
|---|---|---|
| C T CORPORATION SYSTEM | Agent | 28 LIBERTY STREET, NEW YORK, NY, 10005 |
| Name | Role | Address |
|---|---|---|
| c/o C T CORPORATION SYSTEM | DOS Process Agent | 28 LIBERTY STREET, NEW YORK, NY, United States, 10005 |
| Filing Number | Date Filed | Type | Effective Date |
|---|---|---|---|
| 220712001981 | 2022-07-12 | APPLICATION OF AUTHORITY | 2022-07-12 |
| Contract Type | Award or IDV Flag | PIID | Start Date | Current End Date | Potential End Date | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PURCHASE ORDER | AWARD | HT942524P0042 | 2024-04-08 | 2024-11-07 | 2024-11-07 | |||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Obligated Amount | 249993.28 |
| Current Award Amount | 249993.28 |
| Potential Award Amount | 249993.28 |
Description
| Title | MEDICAL R AND D PURCHASE ORDER FOR A DHA STTR PHASE I, PROPOSAL NO. H23C-001-0042, TITLED, "DEVELOPMENT OF ANTI-GLYCAN ANTIBODIES AGAINST MULTI-DRUG RESISTANT ESKAPE WOUND PATHOGENS" |
| NAICS Code | 541715: RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) |
| Product and Service Codes | AN11: HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH |
Recipient Details
| Recipient | GLYPHIC BIOTECHNOLOGIES, INC. |
| UEI | F57WT7JZDH19 |
| Recipient Address | UNITED STATES, 169 MADISON AVE, STE 2216, NEW YORK, NEW YORK, NEW YORK, 100165101 |
Date of last update: 10 Jan 2025
Sources: New York Secretary of State
